Methods for Treating Type 2 Diabetes in Patients Resistant to Previous Treatment with other Anti-Diabetic Drugs Employing an SGLT2 Inhibitor and Compositions Thereof
作者： Paul Strumph , James List , Stephanie Moran
DOI:
关键词:
摘要: The invention provides methods for treating a patient having type 2 diabetes who has failed on previous regimens of one or more oral and/or injectable anti-diabetic agents, which include the step administering therapeutically effective amount an SGLT2 inhibitor alone in combination with another agent other therapeutic to such patient. A pharmaceutical composition containing dapagliflozin dapagliflozin-S-propylene glycol solvate and diabetic agents use is also provided.
google.it 参考文章(30)
Joaquim Fernando Tomaz Rodrigues Moita Calado, Dapagliflozin, an oral sodium glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus. IDrugs : the investigational drugs journal. ,vol. 12, pp. 785- 798 ,(2009)
Masayuki Isaji, Sodium-glucose cotransporter inhibitors for diabetes. Current opinion in investigational drugs. ,vol. 8, pp. 285- 292 ,(2007)
Ramesh Sesha, Novel sglt2 inhibitor dosage forms ,(2009)
G. K. Brown, Glucose transporters: Structure, function and consequences of deficiency Journal of Inherited Metabolic Disease. ,vol. 23, pp. 237- 246 ,(2000) , 10.1023/A:1005632012591
M. K. Poulsen, J. E. Henriksen, O. Hother-Nielsen, H. Beck-Nielsen, The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients. Diabetes Care. ,vol. 26, pp. 3273- 3279 ,(2003) , 10.2337/DIACARE.26.12.3273
C. Smith, M.J. Ashton, R.C. Bush, V. Facchini, N.V. Harris, T.W. Hart, R. Jordan, R. MacKenzie, D. Riddell, RP 73163: A bioavailable alkylsulphinyl-diphenylimidazole ACAT inhibitor Bioorganic & Medicinal Chemistry Letters. ,vol. 6, pp. 47- 50 ,(1996) , 10.1016/0960-894X(95)00555-8
Michael J. Ryan, Gretchen Johnson, Judy Kirk, Sally M. Fuerstenberg, Richard A. Zager, Beverly Torok-Storb, HK-2: An immortalized proximal tubule epithelial cell line from normal adult human kidney Kidney International. ,vol. 45, pp. 48- 57 ,(1994) , 10.1038/KI.1994.6
L. Zhang, Y. Feng, J. List, S. Kasichayanula, M. Pfister, Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes, Obesity and Metabolism. ,vol. 12, pp. 510- 516 ,(2010) , 10.1111/J.1463-1326.2010.01216.X
B Komoroski, N Vachharajani, Y Feng, L Li, D Kornhauser, M Pfister, Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clinical Pharmacology & Therapeutics. ,vol. 85, pp. 513- 519 ,(2009) , 10.1038/CLPT.2008.250
William N. Washburn, Bruce Ellsworth, Philip M. Sher, Wei Meng, Gang Wu, C-aryl glucoside SGLT2 inhibitors and method ,(2003)